{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:18:30Z","timestamp":1775074710363,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jtha.2022.10.014","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T06:17:50Z","timestamp":1673158670000},"page":"164-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2987-281X","authenticated-orcid":false,"given":"Gary W.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-0552","authenticated-orcid":false,"given":"Elisabetta","family":"Castoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-803X","authenticated-orcid":false,"given":"Jun","family":"Teruya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-3363","authenticated-orcid":false,"given":"Eriko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-6272","authenticated-orcid":false,"given":"Dorothy M.","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.10.014_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1538-7836.2009.03711.x","article-title":"APC resistance: biological basis and acquired influences","volume":"8","author":"Castoldi","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.90.3.1004","article-title":"Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C","volume":"90","author":"Dahlb\u00e4ck","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2022.10.014_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2022.10.014_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ajh.23867","article-title":"Activated protein C resistance testing for factor V Leiden","volume":"89","author":"Kadauke","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/ajcp\/aqx033","article-title":"Diagnostic testing approaches for activated protein C resistance and factor V Leiden: a comparison of institutional and national provider practices","volume":"147","author":"Perez Botero","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2022.10.014_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0039-1677840","article-title":"Laboratory diagnostics in thrombophilia","volume":"39","author":"Linnemann","year":"2019","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2022.10.014_bib7","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jth.14532","article-title":"Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH","volume":"17","author":"Moore","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2141.2004.05059.x","article-title":"Intraindividual consistency of the activated protein C resistance phenotype","volume":"126","author":"Tosetto","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2141.2004.05055.x","article-title":"Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors","volume":"126","author":"Taralunga","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A\u00a0reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis","volume":"93","author":"de Visser","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","article-title":"Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism","volume":"130","author":"Rodeghiero","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2022.10.014_bib12","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1182\/blood.2020008168","article-title":"Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia","volume":"137","author":"Simioni","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1055\/s-0037-1616135","article-title":"Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis","volume":"86","author":"Castaman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ejhg.2012.242","article-title":"A\u00a0gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array","volume":"21","author":"Gaunt","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jtha.2022.10.014_bib15","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1182\/blood-2003-10-3578","article-title":"Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations","volume":"103","author":"Castoldi","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib16","doi-asserted-by":"crossref","first-page":"31869","DOI":"10.1016\/S0021-9258(18)31776-9","article-title":"The mechanism of inactivation of human factor V and human factor Va by activated protein C","volume":"269","author":"Kalafatis","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib17","doi-asserted-by":"crossref","first-page":"21158","DOI":"10.1074\/jbc.270.36.21158","article-title":"Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C","volume":"270","author":"Nicolaes","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib18","doi-asserted-by":"crossref","first-page":"27852","DOI":"10.1074\/jbc.270.46.27852","article-title":"Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C","volume":"270","author":"Rosing","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib19","doi-asserted-by":"crossref","first-page":"31486","DOI":"10.1016\/S0021-9258(19)84061-9","article-title":"Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va","volume":"281","author":"Norstr\u00f8m","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib20","doi-asserted-by":"crossref","first-page":"18735","DOI":"10.1016\/S0021-9258(17)32228-7","article-title":"Factor V and protein S as synergistic cofactors to activated protein C in the degradation of factor VIIIa","volume":"269","author":"Shen","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib21","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1074\/jbc.M708985200","article-title":"Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V","volume":"283","author":"Gale","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib22","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1182\/blood.V93.8.2552","article-title":"Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V","volume":"93","author":"Thorelli","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib23","doi-asserted-by":"crossref","first-page":"16140","DOI":"10.1074\/jbc.273.26.16140","article-title":"The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V","volume":"273","author":"Thorelli","year":"1998","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib24","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1182\/blood.V97.8.2525","article-title":"Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation","volume":"97","author":"Parker","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib25","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2008-06-162453","article-title":"Low plasma levels of tissue factor pathway inhibitor in patients with\u00a0congenital factor V deficiency","volume":"112","author":"Duckers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V91.4.1140","article-title":"Factor V Cambridge: a new mutation (Arg306\u2013>Thr) associated with resistance to activated protein C","volume":"91","author":"Williamson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib27","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1046\/j.1365-2141.1998.01051.x","article-title":"Factor V Arg306\u2013>Thr (factor V Cambridge) and factor V Arg306\u2013>Gly mutations in venous thrombotic disease","volume":"103","author":"Franco","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1055\/s-0037-1614462","article-title":"The prevalence of factor V Arg306\u2013>Thr (factor V Cambridge) and factor V Arg306\u2013>Gly mutations in different human populations","volume":"81","author":"Franco","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH05-11-0740","article-title":"Factor V Cambridge mutation and activated protein C resistance assays","volume":"95","author":"Le Cam-Duchez","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib30","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1182\/blood.V91.4.1135","article-title":"A\u00a0novel mutation of Arg306 of factor V gene in Hong Kong Chinese","volume":"91","author":"Chan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib31","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V92.7.2599","article-title":"Clinical significance of Arg306 mutations of factor V gene","volume":"92","author":"Liang","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ajh.20233","article-title":"Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial","volume":"78","author":"Ruiz-Arg\u00fcelles","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/1076029607303341","article-title":"Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients","volume":"13","author":"D\u00f6lek","year":"2007","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood-2002-02-0343","article-title":"Functional characterization of recombinant FV Hong Kong and FV Cambridge","volume":"100","author":"Norstr\u00f8m","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00001721-200204000-00006","article-title":"The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model","volume":"13","author":"Van der Neut Kolfschoten","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2022.10.014_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.thromres.2014.11.013","article-title":"Lack of association between factor V Hong Kong and venous thrombosis in the Chinese population","volume":"135","author":"Cheng","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.014_bib37","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2003.04624.x","article-title":"Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C","volume":"123","author":"Mumford","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib38","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/blood-2003-06-2092","article-title":"Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis","volume":"103","author":"Steen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0038-1650290","article-title":"\u201cPseudo homozygous\u201d activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds","volume":"75","author":"Simioni","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cca.2015.02.002","article-title":"Three novel variants in the coagulation factor V gene associated with deep venous thrombosis in Chilean patients with Amerindian ethnic background","volume":"444","author":"Guzm\u00e1n","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jtha.2022.10.014_bib41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/jth.13339","article-title":"Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn) associated with activated protein C resistance","volume":"14","author":"Pezeshkpoor","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib42","doi-asserted-by":"crossref","first-page":"20805","DOI":"10.1074\/jbc.M802703200","article-title":"Mapping of the factor Xa binding site on factor Va by site-directed mutagenesis","volume":"283","author":"Steen","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.10.014_bib43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.thromres.2010.02.009","article-title":"A novel mutation (G2172\u2013>C) in the factor V gene in a Chinese family with hereditary activated protein C resistance","volume":"125","author":"Cai","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.014_bib44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1076029613514130","article-title":"Prevalence of the factor V E666D mutation and its correlation with activated protein C resistance in the Chinese population","volume":"21","author":"Xin-Guang","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib45","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2013-10-530089","article-title":"Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent\u00a0APC resistance relative to FVLeiden","volume":"123","author":"Nogami","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib46","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jth.14594","article-title":"The roles of factor Va and protein S in formation of the activated protein C\/protein S\/factor Va inactivation complex","volume":"17","author":"Gierula","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib47","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/jth.15274","article-title":"Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besan\u00e7on)","volume":"19","author":"Castoldi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib48","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood.V90.4.1552","article-title":"A\u00a0factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype","volume":"90","author":"Bernardi","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12185-010-0547-3","article-title":"Activated protein C resistance in the Japanese population due to homozygosity for the factor V R2 haplotype","volume":"91","author":"Okada","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0037-1613866","article-title":"The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis","volume":"83","author":"de Visser","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0037-1612907","article-title":"Functional properties of factor V and factor Va encoded by the R2-gene","volume":"85","author":"Hoekema","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib52","first-page":"1182","article-title":"The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.10.014_bib53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s004390050499","article-title":"Polymorphism in exon 10 of the human coagulation factor V gene in a population at risk for sickle cell disease","volume":"100","author":"Helley","year":"1997","journal-title":"Hum Genet"},{"key":"10.1016\/j.jtha.2022.10.014_bib54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V86.1.219.bloodjournal861219","article-title":"Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients","volume":"86","author":"Gandrille","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib55","first-page":"963","article-title":"Arg485Lys polymorphism of factor V increases the risk of coronary artery disease in a Chinese population","volume":"113","author":"Le","year":"2000","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jtha.2022.10.014_bib56","first-page":"705","article-title":"A\u00a0polymorphism nt 1628G\u2013>A (R485K) in exon 10 of the coagulation factor V gene may be a risk factor for thrombosis in the indigenous Thai population","volume":"80","author":"Hiyoshi","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib57","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1055\/s-0037-1616777","article-title":"Evidence for an association of the R485K polymorphism in the coagulation factor V gene with severe preeclampsia from screening 35 polymorphisms in 27 candidate genes","volume":"86","author":"Watanabe","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.ejhg.5201124","article-title":"Susceptibility to pre-eclampsia in Finnish women is associated with R485K polymorphism in the factor V gene, not with Leiden mutation","volume":"12","author":"Faisel","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jtha.2022.10.014_bib59","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2005-04-1461","article-title":"An underestimated combination of opposites resulting in enhanced thrombotic tendency","volume":"106","author":"Simioni","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib60","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1538-7836.2011.04205.x","article-title":"Factor V Leiden pseudo-homozygotes have a more pronounced hypercoagulable state than factor V Leiden homozygotes","volume":"9","author":"Duckers","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib61","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"Determinants of the APTT- and ETP-based APC sensitivity tests","volume":"3","author":"de Visser","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib62","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1365-2141.2001.03203.x","article-title":"The phenomenon known as acquired activated protein C resistance","volume":"115","author":"Clark","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib63","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"Jenkins","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib64","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/jth.13113","article-title":"Predictive value of factor\u00a0VIII levels for recurrent venous thrombosis: results from the\u00a0MEGA follow-up study","volume":"13","author":"Timp","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib65","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-2141.2001.03146.x","article-title":"Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism","volume":"115","author":"O\u2019Donnell","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1309\/QCUUNRMVJY8MWPPL","article-title":"Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden","volume":"119","author":"Graf","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2022.10.014_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2018.10.020","article-title":"Elevated coagulation factor levels affect the tissue factor-threshold in thrombin generation","volume":"172","author":"Rietveld","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.014_bib68","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1538-7836.2010.03773.x","article-title":"Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels","volume":"8","author":"Lavigne-Lissalde","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib69","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood.V96.9.3295","article-title":"Hyperprothrombinemia may result in acquired activated protein C reistance","volume":"96","author":"Tripodi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib70","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1538-7836.2007.02448.x","article-title":"Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia","volume":"5","author":"Castoldi","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1160\/TH08-07-0491","article-title":"Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C","volume":"101","author":"Yegneswaran","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib72","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood.V95.5.1714.005k40_1714_1720","article-title":"Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase","volume":"95","author":"O\u2019Brien","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib73","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V95.12.3678.012k45_3678_3682","article-title":"High levels of factor IX increase the risk of venous thrombosis","volume":"95","author":"Vlieg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib74","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1055\/s-0037-1615956","article-title":"Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis","volume":"85","author":"de Visser","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib75","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1538-7836.2009.03363.x","article-title":"Regulation of TFPI function by protein S","volume":"7","author":"Hackeng","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib76","doi-asserted-by":"crossref","first-page":"17838","DOI":"10.1073\/pnas.1310444110","article-title":"Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation","volume":"110","author":"Wood","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2022.10.014_bib77","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/jth.13559","article-title":"The C-terminus of tissue factor pathway inhibitor-alpha inhibits factor V activation by protecting the Arg1545 cleavage site","volume":"15","author":"van Doorn","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib78","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1076029616683802","article-title":"Oral contraceptives and HRT risk of thrombosis","volume":"24","author":"Gialeraki","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib79","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial","volume":"103","author":"Kemmeren","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.014_bib81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2141.1999.01302.x","article-title":"Acquired APC resistance and oral contraceptives: differences between two functional tests","volume":"105","author":"Curvers","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib82","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1055\/s-0042-1753511","article-title":"Laboratory testing for the evaluation of phenotypic activated protein C resistance","volume":"48","author":"Morimont","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib83","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/ijlh.13427","article-title":"Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance","volume":"43","author":"Evrard","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib84","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1055\/s-0037-1615035","article-title":"Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy","volume":"79","author":"Clark","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib85","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1160\/TH04-06-0372","article-title":"Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential","volume":"93","author":"Zotz","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib86","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2141.2011.08712.x","article-title":"Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism","volume":"154","author":"Bergrem","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib87","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/humrep\/16.5.961","article-title":"Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage","volume":"16","author":"Rai","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jtha.2022.10.014_bib88","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bcmd.2015.06.011","article-title":"Factors contributing to APC-resistance in women with recurrent spontaneous miscarriages: Indian perspective","volume":"55","author":"Sharma","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtha.2022.10.014_bib89","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1538-7836.2005.01168.x","article-title":"Mechanisms for acquired activated protein C resistance in cancer patients","volume":"3","author":"Sarig","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib90","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1538-7836.2008.03060.x","article-title":"Increased acquired activated protein C resistance in unselected patients with hematological malignancies","volume":"6","author":"Negaard","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib91","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/ijc.28104","article-title":"Impact of chemotherapy on activated protein C-dependent thrombin generation\u2014association with VTE occurrence","volume":"133","author":"Roselli","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtha.2022.10.014_bib92","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/rheumatology\/keaa509","article-title":"Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?","volume":"60","author":"Ramirez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtha.2022.10.014_bib93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2008.11.006","article-title":"Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus","volume":"124","author":"Nojima","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2022.10.014_bib94","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1182\/blood.V99.11.3985","article-title":"Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations","volume":"99","author":"Kalafatis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.014_bib95","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1309\/AJCP90HZNZBHNXBE","article-title":"Acquired activated protein C resistance caused by lupus anticoagulants","volume":"136","author":"Saenz","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2022.10.014_bib96","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jth.15199","article-title":"Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of a\u03b22GPI and aPS\/PT antibodies","volume":"19","author":"Pontara","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib97","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/ijlh.12419","article-title":"Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance","volume":"37","author":"Moore","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib98","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00001721-200106000-00014","article-title":"Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant","volume":"12","author":"Solano","year":"2001","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2022.10.014_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-11-130","article-title":"Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients","volume":"11","author":"Ayala","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jtha.2022.10.014_bib100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11239-015-1316-1","article-title":"Guidance for the evaluation and treatment of hereditary and acquired thrombophilia","volume":"41","author":"Stevens","year":"2016","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2022.10.014_bib101","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMra1700365","article-title":"Thrombophilia testing and venous thrombosis","volume":"377","author":"Connors","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.10.014_bib102","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.18239","article-title":"Thrombophilia testing: a British Society for Haematology guideline","volume":"198","author":"Arachchillage","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.014_bib103","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1111\/hae.12934","article-title":"Confirmation of genetic testing results in haemostasis and thrombosis\u2014survey of current practice in the field","volume":"22","author":"Jennings","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.10.014_bib104","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/jth.12722","article-title":"Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome","volume":"12","author":"Arachchillage","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jtha.2022.10.014_bib107","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"Douxfils","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2022.10.014_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12612","article-title":"Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay","volume":"5","author":"Morimont","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.014_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","article-title":"Factor V Leiden thrombophilia","volume":"13","author":"Kujovich","year":"2011","journal-title":"Genet Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:32:44Z","timestamp":1761535964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622071835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1538783622071835"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.10.014","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}